Literature DB >> 17242919

Neuroendocrine tumour of the mediastinum: fusion of 18F-FDG and 68Ga-DOTATOC PET/CT datasets demonstrates different degrees of differentiation.

C von Falck1, A R Boerner2, M Galanski3, W H Knapp4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17242919     DOI： 10.1007/s00259-006-0350-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  3 in total

1.  Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.

Authors:  Sophia Koukouraki; Ludwig G Strauss; Vassilios Georgoulias; Michael Eisenhut; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-09       Impact factor: 9.236

Review 2.  (68)Ga-labeled peptides in tumor imaging.

Authors:  Helmut R Maecke; Michael Hofmann; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

3.  Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.

Authors:  S Adams; R Baum; T Rink; P M Schumm-Dräger; K H Usadel; G Hör
Journal:  Eur J Nucl Med       Date:  1998-01
  3 in total
  8 in total

Review 1.  ⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.

Authors:  Valentina Ambrosini; Davide Campana; Paola Tomassetti; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 2.  Peptide-based imaging agents for cancer detection.

Authors:  Xiaolian Sun; Yesen Li; Ting Liu; Zijing Li; Xianzhong Zhang; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2016-06-18       Impact factor: 15.470

Review 3.  The next generation of positron emission tomography radiopharmaceuticals in oncology.

Authors:  Samuel L Rice; Celeste A Roney; Pierre Daumar; Jason S Lewis
Journal:  Semin Nucl Med       Date:  2011-07       Impact factor: 4.446

4.  A novel gallium bisaminothiolate complex as a myocardial perfusion imaging agent.

Authors:  Karl Plössl; Rajesh Chandra; Wenchao Qu; Brian P Lieberman; Mei-Ping Kung; Rong Zhou; Bin Huang; Hank F Kung
Journal:  Nucl Med Biol       Date:  2007-11-19       Impact factor: 2.408

5.  Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.

Authors:  Valentina Ambrosini; Paola Tomassetti; Paolo Castellucci; Davide Campana; Giancarlo Montini; Domenico Rubello; Cristina Nanni; Anna Rizzello; Roberto Franchi; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-17       Impact factor: 9.236

6.  (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours.

Authors:  Valentina Ambrosini; Cristina Nanni; Maurizio Zompatori; Davide Campana; Paola Tomassetti; Paolo Castellucci; Vincenzo Allegri; Domenico Rubello; Giancarlo Montini; Roberto Franchi; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-27       Impact factor: 9.236

7.  FDG PET/CT for the early prediction of RAI therapy response in patients with metastatic differentiated thyroid carcinoma.

Authors:  Seo Young Kang; Ji-In Bang; Keon Wook Kang; Ho-Young Lee; June-Key Chung
Journal:  PLoS One       Date:  2019-06-25       Impact factor: 3.240

8.  A [68Ga]Ga-DOTANOC PET/CT Radiomic Model for Non-Invasive Prediction of Tumour Grade in Pancreatic Neuroendocrine Tumours.

Authors:  Alessandro Bevilacqua; Diletta Calabrò; Silvia Malavasi; Claudio Ricci; Riccardo Casadei; Davide Campana; Serena Baiocco; Stefano Fanti; Valentina Ambrosini
Journal:  Diagnostics (Basel)       Date:  2021-05-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.